top of page
Image by CDC

SCIENCE >  PIPELINE

Pipeline

We are developing targeted therapies addressing high-unmet-need cancers through a diverse and translational oncology pipeline.

PIPELINE

~10

compounds, devices or indications in development individually or under collaboration or license

PRECLINICAL

6

R&D investment in 2025

THERAPEUTICAL AREA

8

programs granted a designation by at least one major regulatory authority to expedite delivery or review in

Hematology

GVT-HM-A101 is a next-generation, highly selective BTK inhibitor designed to achieve sustained target occupancy with minimal off-target effects. It aims to improve safety, including reduced cardiac risk, while providing durable suppression of B-cell receptor signaling in diseases such as CLL and mantle cell lymphoma.

MOLECULE

DISEASE AREA

INVESTIGATIONAL INDICATION

GVT-HM-A101
(BTK Inhibitor)

Hematologic Malignancies

TN CLL/SLL*

Treatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

AML/MDS (+ chemotherapy)

Acute Myeloid Leukemia/Myelodysplastic Syndrome

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

R/R FL (+CD20)*

— Relapsed/Refractory Follicular Lymphoma

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

Solid Tumors

GVT-53038, a PD-1 monoclonal antibody for lung cancer; GVT-C137, an FGFR2B antibody-drug conjugate targeting gastric cancer; and GVT-B455, a CCR8 monoclonal antibody for breast cancer. GVT-B455 also functions as a highly potent and selective CDK2 inhibitor, designed to block elevated Cyclin E/CDK2 activity—a key resistance pathway to standard CDK4/6 inhibitor therapies in HR+/HER2– breast cancer.

GVT-53038 
(PD-1 Monoclonal Antibody)

Lung Cancers

Solid Tumors / Pan-Tumor,

Solid Tumors / Pan-Tumor, NSCLC — Non–Small Cell Lung Cancer

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

GVT-C137
(FGFR2B Antibody Drug Conjugate)

Gastrointestinal Cancers

GI Cancers

Gastric / Gastrointestinal Adenocarcinoma

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

GVT-B455
(CCR8 Monoclonal Antibody)

Breast/Gynecologic Cancers

HR+ Breast Cancer and Solid Tumors

HR+/HER2– Breast Cancer

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

Rare Disease/ Autoimmune/Immune and Inflammation

Genventis’s first-in-class targeted immunotherapy is engineered to modulate immune responses in autoimmune and inflammatory disorders. Developed by Genventis researchers, this therapy is designed to engage key immune pathways, promoting T-cell regulation, cytokine balance, and restoration of immune homeostasis to reduce chronic inflammation and tissue damage.

GVT-7012
(BTK Inhibitor)

Multiple Sclerosis 

Relapsing and Progressive Multiple Sclerosis

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

GVT-7054
(IRAK4 Chimeric Degradation Activation Compound (CDAC))

Rheumatoid Arthritis

Moderate to Severe Rheumatoid Arthritis

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

GVT-7063
(JAK1 Inhibitor)

Inflammatory Bowel Disease

Ulcerative Colitis / Crohn’s Disease

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

The pipeline is updated quarterly. Last updated August 2026.

Safety and efficacy have not been established for investigational products and/or uses. .

* Four compounds are under the approval process in at least one major market, including the USA, EU, China, or Japan, and one compound is in ** Phase 1 confirmatory development.

bottom of page